A Phase 4 interventional study of Dietary advice and rosuvastatin in Hypercholesterolaemia, sponsored by AstraZeneca. Terminated at 9 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2006, is one of 15 in phase 4, and was the 13th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Hypercholesterolemia by AstraZeneca: 3 open now, 3 under way, 3 of them phase 3. Of 55 finished, 7 (13%) have results posted.
Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 30th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2006, is one of 5 in phase 4, and was the 14th registered.
AstraZeneca’s Hypercholesterolemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
rosuvastatin 5 mg
Behavioral: Dietary advice · Drug: rosuvastatin
atorvastatin 10 mg
Behavioral: Dietary advice · Drug: atorvastatin
rosuvastatin 5 mg
Also known as: Crestor
atorvastatin 10 mg
Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)
Calculated as LDL-C at Week 6 - LDL-C at Week 12\] \* 100
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L
Time frame: 6 weeks (Baseline) and 12 weeks
The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.
Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline(week6) in TC
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6)in Non-HDL-C
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
Time frame: 6 weeks (baseline) and 12 weeks
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.
Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.
Time frame: 6 weeks (baseline) and 12 weeks
Participants were recruited from 25 primary and secondary care centres in the United Kingdom. The first participant was enrolled on 20th December 2006 and the last participant entered the study on 16th November 2007.
| Milestone | Rosuvastatin | Atorvastatin |
|---|---|---|
| Started | 30 | 25 |
| Completed | 28 | 21 |
| Not completed | 2 | 4 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Other | 0 | 1 |
Calculated as LDL-C at Week 6 - LDL-C at Week 12\] \* 100
| Percent Change in LDL-C | Rosuvastatin | Atorvastatin |
|---|---|---|
| Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C) | 33.28 | 36.92 |
| Percentage of Participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L | 50 | 64 |
| Percentage of Participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L | 16 | 28 |
Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.
| Percentage of Participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category. | 43 | 48 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in TC | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline(week6) in TC | -23.03 | -26.88 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in HDL-C | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C) | 4.46 | 3.15 |
| Percentage of Participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L | 13 | 12 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in Non-HDL-C | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6)in Non-HDL-C | -29.72 | -34.09 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in ApoB | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB) | -25.96 | -28.67 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in ApoA1 | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1) | -0.55 | 1.89 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in LDL-C/HDL-C Ratio | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio | -34.75 | -38.45 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in TC/HDL-C Ratio | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio | -24.99 | -28.42 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in Non-HDL-C/HDL-C Ratio | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio | -31.05 | -35.48 |
Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6
| Percent Change in ApoB/ApoA1 Ratio | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio | -22.89 | -28.75 |
Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.
| Percentage of Participants | Rosuvastatin | Atorvastatin |
|---|---|---|
| The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category. | 56.7 | 56.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin | — | — | — |
| Atorvastatin | — | — | — |
| Event | Rosuvastatin | Atorvastatin |
|---|---|---|
| Cerebrovascular AccidentNervous system disorders | 1/30 | 0/30 |
| Event | Rosuvastatin | Atorvastatin |
|---|---|---|
| DizzinessNervous system disorders | 3/30 | 1/25 |
| HeadacheNervous system disorders | 1/30 | 2/25 |
| Age Continuous(years) | Rosuvastatin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 50 ± 11 | 53 ± 11 | 51.5 ± 11 |
| Sex: Female, Male(Participants) | Rosuvastatin | Atorvastatin | Total |
|---|---|---|---|
| Female | 13 | 11 | 24.0 |
| Male | 17 | 14 | 31.0 |
The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Atorvastatin